Analysis of LEADER trial shows liraglutide reduces cardiovascular risk in people with type 2 diabetes, regardless of severe hypoglycaemia

  New findings from a post-hoc analysis of the LEADER cardiovascular (CV) outcomes trial found that treatment with Victoza (liraglutide) 1.8mg once daily, resulted in similar reductions in the risk of major CV events in adults with type 2 diabetes (T2D) at high CV risk, regardless of whether or not they experienced an episode of severe hypoglycaemia during the trial. The findings were presented at the 77th annual Scientific Sessions of the American Diabetes Association (ADA). For the overall LEADER population, regardless of treatment group, people who experienced a severe hypoglycaemic episode were at a significantly greater risk of major